臨床整形外科54巻7号

2019年07月発行

誌上シンポジウム 骨軟部腫瘍の薬物治療アップデート

骨転移に対する骨修飾薬治療

著者： 篠田裕介¹

所属機関： ¹東京大学医学部附属病院リハビリテーション科

ページ範囲：P.671 - P.676

　骨転移患者に対する整形外科の役割は，骨折・麻痺のリスク評価・管理を行い，疼痛の原因を明らかにし，治療を行うことでactivities of daily living(ADL)を維持することである．骨修飾薬は，骨粗鬆症にも使用される薬剤であり，整形外科医にとってもなじみがある薬である．骨折や麻痺を予防するために有用な治療であるため，整形外科医はこれらの原理や使用方法，効果に精通している必要があり，骨転移の患者に対して，まずは骨修飾薬の投与を検討すべきである．本稿では，骨転移の治療方針，骨修飾薬の原理，具体的な使用方法，副作用について概説する．

参考文献

1) Hirai T, Shinoda Y, Tateishi R, et al. Early detection of bone metastases of hepatocellular carcinoma reduces bone fracture and paralysis. Jpn J Clin Oncol 2019;49:529-36.

2) 日本臨床腫瘍学会(編)．骨転移診療ガイドライン．東京：南江堂；2015．

3) Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68.

4) Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 2005;23(15):3314-21. Epub 2005 Feb 28.

5) Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-7.

6) Omae K, Tsujimoto Y, Honda M, et al. Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma:a systematic review and meta-analysis. Oncotarget 2017;8(40):68890-8. doi:10.18632/oncotarget.20323. eCollection 2017 Sep 15.

7) Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma:an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19(3):370-81. doi:10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

8) Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9. doi:10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

9) Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 2011;377(9768):813-22. doi:10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

10) Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32. doi:10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

11) Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events:a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48(16):3082-92. doi:10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

12) Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid:subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7(12):1823-9. doi:10.1097/JTO.0b013e31826aec2b.

13) Kinoshita Y, Arai M, Ito N, et al. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocr J 2016;63(5):479-84. doi:10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9.